Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species.
Willis BA, Lowe SL, Monk SA, Cocke PJ, Aluise CD, Boggs LN, Borders AR, Brier RA, Dean RA, Green SJ, James DE, Jhee SS, Lin Q, Lo AC, May PC, Watson BM, Winneroski LL, Yang Z, Zimmer JA, McKinzie DL, Mergott DJ. Willis BA, et al. Among authors: zimmer ja. J Alzheimers Dis Rep. 2022 Jan 11;6(1):1-15. doi: 10.3233/ADR-210037. eCollection 2022. J Alzheimers Dis Rep. 2022. PMID: 35243208 Free PMC article.
Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
Sims JR, Selzler KJ, Downing AM, Willis BA, Aluise CD, Zimmer J, Bragg S, Andersen S, Ayan-Oshodi M, Liffick E, Eads J, Wessels AM, Monk S, Schumi J, Mullen J. Sims JR, et al. J Prev Alzheimers Dis. 2017;4(4):247-254. doi: 10.14283/jpad.2017.38. J Prev Alzheimers Dis. 2017. PMID: 29181490 Review.
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR. Wessels AM, et al. Among authors: zimmer ja. JAMA Neurol. 2020 Feb 1;77(2):199-209. doi: 10.1001/jamaneurol.2019.3988. JAMA Neurol. 2020. PMID: 31764959 Free PMC article. Clinical Trial.
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Zimmer JA, Shcherbinin S, Devous MD Sr, Bragg SM, Selzler KJ, Wessels AM, Shering C, Mullen J, Landry J, Andersen SW, Downing AM, Fleisher AS, Svaldi DO, Sims JR. Zimmer JA, et al. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12123. doi: 10.1002/trc2.12123. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33614894 Free PMC article.
How donanemab data address the coverage with evidence development questions.
Klein EG, Schroeder K, Wessels AM, Phipps A, Japha M, Schilling T, Zimmer JA. Klein EG, et al. Among authors: zimmer ja. Alzheimers Dement. 2024 Apr;20(4):3127-3140. doi: 10.1002/alz.13700. Epub 2024 Feb 7. Alzheimers Dement. 2024. PMID: 38323738 Free PMC article. Review.
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials.
Lu M, Pontecorvo MJ, Devous MD Sr, Arora AK, Galante N, McGeehan A, Devadanam C, Salloway SP, Doraiswamy PM, Curtis C, Truocchio SP, Flitter M, Locascio T, Devine M, Zimmer JA, Fleisher AS, Mintun MA; AVID Collaborators. Lu M, et al. Among authors: zimmer ja. JAMA Neurol. 2021 Apr 1;78(4):445-453. doi: 10.1001/jamaneurol.2020.5505. JAMA Neurol. 2021. PMID: 33587110 Free PMC article. Clinical Trial.
27 results